Mumbai : The Indian Pharmaceutical Market (IPM) has registered a growth of 13.7 per cent for the month of July 2021, after registering a growth of 14.1 per cent for the month of June 2021.
According to AIOCD AWACS report, moving annual total (MAT) for the July was at Rs. 172,588 crore, which has seen a growth of 16 per cent over the corresponding period of last year.
Sun Pharma maintained number one position at Rs. 1,132 crore sales followed by Abbott (Rs. 927 crore), Cipla (Rs. 754 crore), Alkem (Rs. 624 crore), and Mankind (Rs. 610 crore).
Top 1 to 10 companies contributed 42 per cent, while top 11 to 20 companies contributed 22 per cent top 21 to 30 companies contributed 9 per cent and top 31 to 40 companies contributed 6 per cent.
Mixtrad of Abbott returns to number one position for the month clocking with Rs. 73 crore sales and Glycomet of USV at number two with a sales of Rs. 55 crore.
“Though drugs with a role to play in Covid treatment/prevention/side-effect management are still dominating the growth, a significant recovery in growth is seen in other section of IPM as well,” stated AIOCD AWACS report.
Cardiac registered a monthly growth of 12 per cent, while antibiotics registered growth of 9 per cent in July 2021. Respiratory medicines registered 7 per cent growth, while anti-infectives exhibited growth of 12 per cent during July 2021.
Vitamins have shown 8 per cent growth, while dermatology products posted 8 per cent growth during July 2021 and gastrointestinal at 11 per cent growth.
In the month of July, Indian companies grown at 16 per cent and MNCs grown at 11 per cent.
India Ratings and Research stated that the 13.7 per cent yoy revenue growth in IPM during July 2021 was led by continued demand normalisation post the high growth months of April 2021 (51.5 per cent growth) and May 2021 (47.8 per cent), while the growth in June 2021 was lower at 14.1 per cent.